notes to the Consolidated financial statementsfor the year ended 30 June 2013
Subsidiary and joint venture | Effective interest in capital | Investment in subsidiaries and joint ventures | Profit/(loss) after taxation | |||||
Name of company | Country of incorporation | Nature of business | 2013 % | 2012 % | 2013 R’000 | 2012 R’000 | 2013 R’000 | 2012 R’000 |
Clover SA | South Africa | Dairy manufacturing, distribution, sales | 100 | 100 | 359 616 | 350 050 | 99 763 | 169 298 |
---|---|---|---|---|---|---|---|---|
Real Juice Co | South Africa | Manufacturing and sales of fruit juices | 100 | – | 174 627 | – | 22 188 | – |
Clover Botswana | Botswana | Dairy manufacturing, distribution, sales | 100 | 100 | 23 111 | 23 111 | 24 940 | 21 202 |
CloverManhattan@ | South Africa | Distribution and sales of ice tea | 100 | 50,1 | – | 3 034 | 863 | 1 120 |
Clover Swaziland | Swaziland | Distribution and sales of dairy products in Swaziland | 100 | 100 | 1 | 1 | (869) | (77) |
Lactolab | South Africa | Testing of dairy products | 52 | 52 | – | – | 2 568 | 2 087 |
Clover Capital | South Africa | Finance | 100 | 100 | 434 744 | 91 000 | – | – |
Clover Fonterra# | South Africa | Marketing, selling and distribution of dairy and related ingredient products | 51 | 51 | 3 060 | 3 060 | 14 221 | 12 297 |
Clover West Africa | Nigeria | Marketing of non-alcoholic beverage products | 100 | 100 | 468 | 468 | (9 841) | (10 539) |
Clover Namibia | Namibia | Distribution and sales of dairy products in Namibia | 100 | 100 | – | – | (13) | (2 752) |
Group | Company | ||||||
2013 R’000 |
2012 R’000 |
2013 R’000 |
2012 R’000 |
||||
32. |
Share-based payments |
||||||
32.1 |
Equity-settled share appreciation rights scheme |
||||||
– Clover Share Appreciation Rights Plan (2010) (ordinary shares in CIL) On 31 May 2010 the ordinary and preference shareholders approved the Clover Share Appreciation Rights Plan (2010) as well as the placement of 8 million unissued ordinary shares under the control of the Directors to fulfil the Company’s potential future obligations in terms of the plan. The main rules of the scheme are as follows: The Company’s obligations in terms of this plan can at the election of the Company be settled in cash or by the issue of ordinary shares. New SAR may be encashed at the election of the participants, at any time after they have vested, provided that the participant concerned is still in the employment of Clover. On encashment employees will be paid an amount equal to the difference between the fair market value of ordinary shares on the date of issue of the new SAR in question and the fair market value of the ordinary shares on the date of encashment. Further details on the scheme are available in the detailed circular issued to shareholders on 7 May 2010 and the remuneration report here. The SAR granted are expensed over their vesting period in terms of IFRS 2. The estimated fair value of these SAR was calculated using the Hull-White Trinomial Lattice valuation model. The following inputs were used for the calculation of the fair value: Initial allocation – Expected volatility of 30,3%, risk free rate of 8,90% and a dividend yield of 2,34%. Second allocation – Expected volatility of 14,9%, risk free rate of 8,90% and a dividend yield of 2,34%. Third allocation – Expected volatility of 19,9%, risk free rate of 8,55% and a dividend yield of 3,33%. Allocation to new Executive Committee member – Expected volatility of 17,4%, risk free rate of 7,94% and a dividend yield of 2,00%. Fourth allocation – Expected volatility of 17,4%, risk free rate of 7,94% and a dividend yield of 2,00% Allocation to new Executive Committee member – Expected volatility of 23,3%, risk free rate of 7,94% and a dividend yield of 2,18%. |
Share appreciation rights | ||||||
Description | Grant date | Weighted average remaining contractual life (years) |
Exercise price | SAR granted not yet exercised |
Estimated weighted average fair value per right at grant date (Adjusted for 2 for 1 share split | Vesting period |
Clover’s Share Appreciation Rights Plan (2010) – Initial allocation | 31 May 2010 | * Till employment terminates | R4,67 | 12 676 780 (2012: 15 500 000) |
R2,11 | One-third on 31 May 2013, a further third on 31 May 2014 and a final third on 31 May 2015 |
Clover’s Share Appreciation Rights Plan (2010) – Second allocation |
18 August 2010 | * Till employment terminates | R0,00 | 933 335 (2012: 1 466 667) |
R4,31 | One-third on 18 August 2011, a third on 18 August 2012 and final third on 18 August 2013 |
Clover’s Share Appreciation Rights Plan (2010) – Third allocation | 1 July 2011 | Six years | R11,00 | 1 614 939 (2012: 2 093 918) |
R3,11 | Full allocation vest on 1 July 2014 |
Clover’s Share Appreciation Rights – Allocation to Executive Committee member ER Bosch | 1 June 2012 | Seven years | R13,50 | 953 620 (2012: 953 620) |
R4,03 | One-third on 1 June 2015, one-third on 1 June 2016 and a final third on 1 June 2017 |
Clover’s Share Appreciation Rights Plan (2010) – Fourth allocation | 1 July 2012 | Seven years | R13,73 | 2 737 742 (2012: Nil) |
R3,70 | Full allocation vest on 1 July 2015 |
Clover’s Share Appreciation Rights Plan (2010) – Allocation to Executive Committee member MM Palmeiro |
1 October 2012 | Seven years | R15,15 | 925 500 (2012: Nil) |
R3,95 | One-third on 1 October 2015, a third on 1 October 2016 and a final third on 1 October 2017 |
Group | Company | |||
2013 R’000 |
2012 R’000 |
2013 R’000 |
2012 R’000 |
|
Provision against income | ||||
18 407 | 13 115 | Share-based payment reserve | ||
33. |
Directors’ remuneration and interests |
33.1 Directors’ remuneration |
2013 | |||||||||
Basic salary R’000 |
Fees for services as Director R’000 |
Car
allow- ance R’000 |
Individual
perfor- mance bonus R’000 |
Profit share bonus |
Retire- ment and medical contri butions R’000 |
Other benefits* R‘000 | Total R’000 | Share
apprecia- tion rights exercised R’000 |
|
Executive Directors | |||||||||
JH Vorster | 3 778 | 1 048 | 1 454 | 1 615 | 761 | 57 | 8 713 | 8 498 | |
HB Roode (retired 30 June 2013) | 2 863 | 816 | 931 | 1 034 | 541 | 43 | 6 228 | 11 967 | |
LJ Botha | 2 587 | 733 | 832 | 925 | 487 | 51 | 5 615 | – | |
CP Lerm(Dr) | 2 240 | 664 | 975 | 696 | 438 | 41 | 5 054 | 11 852 | |
Total remuneration of Executive Directors | 11 468 | – | 3 261 | 4 192 | 4 270 | 2 227 | 192 | 25 610 | 32 317 |
Non-Executive Directors | |||||||||
JAH Bredin (resigned 30 November 2012) | 490 | 9 | 499 | ||||||
HPF du Preez (resigned 30 November 2012) | 136 | – | 136 | ||||||
WI Büchner | 747 | – | 747 | ||||||
MG Elliot | 272 | 46 | 318 | ||||||
JC Hendriks (Dr) | 342 | 26 | 368 | ||||||
TA Wixley | 739 | – | 739 | ||||||
SF Booysen (Dr) | 513 | 17 | 530 | ||||||
NP Mageza | 383 | – | 383 | ||||||
JNS Du Plessis (Adv) | 435 | 34 | 469 | ||||||
NA Smith | 272 | 16 | 288 | ||||||
Total remuneration of Non-Executive Directors | – | 4 329 | – | – | – | – | 148 | 4 477 | – |
Total Directors’ remuneration | 11 468 | 4 329 | 3 261 | 4 192 | 4 270 | 2 227 | 340 | 30 087 | 32 317 |
Other Executives (prescribed officers) | |||||||||
H Lubbe | 2 256 | 655 | 975 | 696 | 440 | 55 | 5 077 | 9 897 | |
JHF Botes (Dr) | 2 266 | 657 | 975 | 696 | 441 | 46 | 5 081 | 6 895 | |
ER Bosch | 2 283 | 629 | 1 219 | 580 | 456 | 70 | 5 237 | – | |
MM Palmeiro (appointed 1 October 2012) | 930 | 264 | 398 | 190 | 172 | 336 | 2 290 | – | |
Total remuneration of other Executives | 7 735 | – | 2 205 | 3 567 | 2 162 | 1 509 | 507 | 17 685 | 16 792 |
* Travel and accommodation expenses, fees paid for directorships held in subsidiaries. |
2012 | |||||||||
Basic salary R’000 |
Fees for services as Director R’000 |
Car allow- ance R’000 |
Individual
perfor- mance bonus R’000 |
Profit share bonus |
Retire- ment and medical contri butions R’000 |
Other benefits* R‘000 | Total R’000 | Share
apprecia - tion rights exercised R’000 |
|
Executive Directors | |||||||||
JH Vorster | 3 498 | 979 | 2 243 | 2 020 | 673 | 60 | 9 473 | – | |
HB Roode | 2 651 | 754 | 1 482 | 1 334 | 462 | 75 | 6 758 | 1 468 | |
LJ Botha | 2 395 | 672 | 1 339 | 1 206 | 391 | 48 | 6 051 | 1 504 | |
CP Lerm (Dr) | 1 989 | 581 | 1 111 | 1 002 | 355 | 198 | 5 236 | 489 | |
Total remuneration of Executive Directors | 10 533 | – | 2 986 | 6 175 | 5 562 | 1 881 | 381 | 27 518 | 3 461 |
Non-Executive Directors | |||||||||
JAH Bredin | 907 | 20 | 927 | ||||||
HPF du Preez | 252 | 3 | 255 | ||||||
WI Büchner | 417 | – | 417 | ||||||
MG Elliot | 252 | 31 | 283 | ||||||
JC Hendriks (Dr) | 329 | 27 | 356 | ||||||
TA Wixley | 684 | – | 684 | ||||||
SF Booysen (Dr) | 437 | 6 | 443 | ||||||
NP Mageza | 354 | – | 354 | ||||||
JNS Du Plessis (Adv) | 431 | 43 | 474 | ||||||
NA Smith | 252 | 14 | 266 | ||||||
Total remuneration of Non-Executive Directors | – | 4 315 | – | – | – | – | 144 | 4 459 | – |
Total Directors’ remuneration | 10 533 | 4 315 | 2 986 | 6 175 | 5 562 | 1 881 | 525 | 31 977 | 3 461 |
Other Executives (prescribed officers) | |||||||||
H Lubbe | 1 882 | 537 | 1 052 | 947 | 299 | 52 | 4 769 | 489 | |
JHF Botes (Dr) | 1 879 | 536 | 1 051 | 946 | 300 | 39 | 4 751 | 489 | |
ER Bosch (appointed 1 June 2012) | 190 | 52 | 17 | 6 | 265 | ||||
Total remuneration of other Executives | 3 951 | – | 1 125 | 2 103 | 1 893 | 616 | 97 | 9 785 | 978 |
* Travel and accommodation expenses, fees paid for directorships held in subsidiaries. |
35. Events after the reporting period
On 1 August 2013 Clover SA acquired 70% of Clover Waters. Refer to directors’ report for more detailed information.
Other than the above, no significant events occurred subsequent to the year-end.